What is the appropriate management for a patient with upper‑mid rectal wall thickening and mesorectal fat stranding on MRI, small presacral/mesorectal lymph nodes, and colonoscopic biopsy showing a villous adenoma with high‑grade dysplasia where invasive carcinoma cannot be excluded?

Management of Upper-Mid Rectal Villous Adenoma with High-Grade Dysplasia

This patient requires formal radical oncologic resection with total mesorectal excision (TME) surgery, not local excision, because the biopsy cannot exclude invasive malignancy and the MRI findings suggest possible malignant features with mesorectal fat stranding and lymph nodes. 1

Rationale for Surgical Approach

Why Local Excision is Inappropriate

• Local excisional procedures such as transanal endoscopic microsurgery (TEM) are only appropriate for early cancers (cT1N0) without adverse features like poor differentiation, vascular invasion, or lymphatic invasion 1
• Your patient has concerning features that preclude local excision: the pathology cannot rule out invasive malignancy, there is mesorectal fat stranding on MRI (suggesting possible extramural extension), and small lymph nodes are present in the mesorectal/presacral space 1
• Giant villous adenomas (particularly >8 cm) carry an 83% combined risk of dysplasia/malignancy, with frank malignancy present in 33% of cases, making them unsuitable for endoscopic or transanal approaches 2

Standard Surgical Management

• The standard of care is TME surgery, which involves meticulous excision of all mesorectal fat including all lymph nodes 1
• For upper-mid rectal tumors, laparoscopic low anterior resection with TME and D2 lymph node dissection is the appropriate procedure 3, 2
• At least 12 regional lymph nodes must be examined pathologically, with documentation of proximal, distal, and circumferential resection margins in millimeters 1

Preoperative Staging Completion

Before proceeding to surgery, ensure complete staging:

• Pelvic MRI assessment should specifically evaluate for extramural venous invasion (EMVI), T substage, and distance to the circumferential resection margin (CRM) 1, 4
• CT scan of thorax and abdomen to exclude distant metastases 1
• Serum CEA level 1
• The mesorectal fat stranding you describe may represent EMVI or inflammatory changes—this distinction is critical for determining need for neoadjuvant therapy 4

Neoadjuvant Therapy Considerations

A critical caveat: Upper rectal cancers (>12 cm from the anal verge) above the peritoneal reflection do not benefit from preoperative short-course preoperative radiotherapy (SCPRT) or chemoradiotherapy (CRT) and should be treated as colon cancer with upfront surgery 1

For mid-rectal tumors, neoadjuvant therapy decisions depend on:

• If MRI predicts threatened CRM (≤1 mm), presence of EMVI, or advanced T3 substages (T3c/T3d), then CRT is indicated before surgery 1
• If the tumor appears completely resectable with negative margins predicted, proceed directly to TME surgery 1
• The small lymph nodes at 5-6 o'clock position warrant careful evaluation—if these suggest N1 disease with threatened margins, neoadjuvant therapy should be considered 1

Key Pitfalls to Avoid

• Do not attempt piecemeal endoscopic resection for large villous adenomas when invasion cannot be excluded—this risks incomplete excision and upstaging 2
• Do not assume benignity based on "adenoma" terminology—villous adenomas >2 cm have up to 50% malignancy risk 2
• Ensure the pathologist performs thorough sampling of the final specimen, as unsuspected invasive carcinoma is found in a significant proportion of these lesions 2
• The presence of mesorectal fat stranding should not be dismissed as inflammatory—it may represent extramural tumor extension requiring oncologic resection 4, 5